The US Food and Drug Administration has announced safety labeling changes and post-market study requirements for extended-release and long-acting opioid analgesics.
The new regulations aim to cut the number of deaths per year from opioid dependence. Earlier this year the Center for Disease Control’s Vital Signs report showed that prescription painkiller overdoses killed nearly 48,000 women between 1999 and 2010 ( The Pharma Letter July 3).
The class-wide labeling changes will include important new language to help health care professionals tailor their prescribing decisions based on a patient’s individual needs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze